AC Immune Showcasing Its Novel Morphomer-Antibody Drug Conjugate (MorADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune Showcasing Its Novel Morphomer-Antibody Drug Conjugate (MorADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune 在 AAIC 2024 上展示其用於治療神經退行性疾病的新型形態組抗體藥物偶聯物 (morADC) 平台
-
Three oral presentations at the Alzheimer's Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626
- 在阿爾茨海默氏症協會國際會議(AAIC 2024)上的三場口頭演講,包括關於 morADC、ACI-24.060 和 ACI-19626 的演講
Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer's Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024.
瑞士洛桑,2024年7月16日——AC Immune SA(納斯達克股票代碼:ACIU)是一家開創神經退行性疾病精準醫療的臨床階段生物製藥公司,今天在2024年7月28日至8月1日在賓夕法尼亞州費城舉行的年度阿爾茨海默氏症協會國際會議(AAIC 2024)上宣佈了三場口頭演講,重點介紹了其精準醫療產品線。
Presentation details (all times are EDT)
演示詳情(所有時間均爲美國東部夏令時間)
Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer
Date: Monday, July 29, 2024 | 2:50 PM – 3:00 PM
Location: Hall A - Pennsylvania Convention Center
Presenter: Tamara Seredenina, PhD (AC Immune)
[18F] ACI-19626 的發現和臨床前開發,這是一款同類首創的 TDP-43-PET 示蹤劑
日期:2024 年 7 月 29 日,星期一 | 下午 2:50 — 下午 3:00
地點:A廳-賓夕法尼亞會議中心
主持人:塔瑪拉·塞雷德尼娜博士(AC Immune)
Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies
Date: Tuesday, July 30, 2024 | 9:40 AM – 9:50 PM
Location: 201 ABC - Pennsylvania Convention Center
Presenter: Emma Fiorini, PhD (AC Immune)
主動免疫療法 ACI-24.060 可誘導抗 ABETA 抗體,其結合特徵反映經臨床驗證的單克隆抗體
日期:2024 年 7 月 30 日,星期二 | 上午 9:40 — 晚上 9:50
地點:201 ABC-賓夕法尼亞會議中心
主持人:艾瑪·菲奧里尼博士(AC Immune)
A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer- Antibody Drug Conjugates)
Date: Wednesday, July 31, 2024 | 8:07 AM – 8:14 AM
Location: 118 ABC - Pennsylvania Convention Center
Presenter: Madiha Derouazi, PhD (AC Immune)
一類新的神經退行性抗病藥物:morADC(形態體-抗體藥物偶聯物)
日期:2024 年 7 月 31 日,星期三 | 上午 8:07 — 上午 8:14
地點:118 ABC-賓夕法尼亞會議中心
主持人:Madiha Derouazi,博士(AC Immune)
Poster details
#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer's disease and Down Syndrome-related Alzheimer's disease
Date: Tuesday, July 30, 2024 | 8:00 AM – 4:15 PM
Location: Exhibit Hall - Pennsylvania Convention Center
Presenter: Michael Rafii, MD, PhD (Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA)
海報詳情
#18 散發性阿爾茨海默病和唐氏綜合徵相關阿爾茨海默病臨床終點進展率的比較分析
日期:2024 年 7 月 30 日,星期二 | 上午 8:00 — 下午 4:15
地點:賓夕法尼亞會議中心展廳
主持人:邁克爾·拉菲,醫學博士(美國加利福尼亞州聖地亞哥南加州大學阿爾茨海默氏症治療研究所)
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties.
AC Immune SA
AC Immune SA是一家臨床階段的生物製藥公司,也是神經退行性疾病精準醫療領域的全球領導者,這些疾病包括阿爾茨海默氏病、帕金森氏病和由錯誤摺疊的蛋白質驅動的NeuroOrphan適應症。該公司的兩個經過臨床驗證的技術平台SupraAntigen和Morphomer爲其廣泛而多元化的一流和一流資產管道提供了動力。這些資產目前包括16個治療和診斷項目,其中5個目前處於2期臨床試驗,一個處於3期。AC Immune在與全球領先製藥公司建立戰略合作伙伴關係方面有着良好的記錄,從而在潛在的里程碑付款和特許權使用費中獲得了大量的非稀釋性資金。
SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
SupraAntigen 是 AC Immune SA 在以下地區的註冊商標:澳大利亞、歐盟、瑞士、英國、日本、俄羅斯、新加坡和美國。Morphomer 是 AC Immune SA 在中國、瑞士、英國、日本、韓國、挪威和俄羅斯的註冊商標。
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
我們網站上的信息以及此處引用的任何其他網站上的信息明確未以引用方式納入本新聞稿中,也不構成本新聞稿的一部分。
For further information, please contact:
欲了解更多信息,請聯繫:
Head of Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com |
U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
投資者關係與企業傳播主管 加里·瓦安德斯,博士,工商管理碩士 AC 免疫 電話:+41 21 345 91 91 電子郵件:gary.waanders@acimmune.com |
美國投資者 科裏·戴維斯博士 生命科學顧問 電話:+1 212 915 2577 電子郵件:cdavis@lifesciadvisors.com |
國際媒體 克里斯·馬戈斯 凝聚力局 電話:+41 79 367 6254 電子郵件:chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward- looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
前瞻性陳述
本新聞稿包含構成1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的 “前瞻性陳述” 的聲明。前瞻性陳述是歷史事實以外的陳述,可能包括針對未來運營、財務或業務業績或AC Immune戰略或預期的陳述。在某些情況下,你可以用前瞻性詞語來識別這些陳述,例如 “可能”、“可能”、“將”、“應該”、“期望”、“計劃”、“預期”、“相信”、“估計”、“預測”、“項目”、“潛力”、“展望” 或 “繼續”,以及其他類似的術語。前瞻性陳述基於管理層當前的預期和信念,涉及重大風險和不確定性,可能導致實際業績、發展和業務決策與這些陳述所設想的結果存在重大差異。這些風險和不確定性包括 “第 3 項” 標題下描述的風險和不確定性。關鍵信息——風險因素” 和 “第 5 項。運營和財務回顧與展望” 載於AC Immune的20-F表年度報告以及向美國證券交易委員會提交的其他文件。前瞻性陳述僅代表其發表之日,除非適用法律另有要求,否則AC Immune不承擔任何義務根據新信息、未來發展或其他情況對其進行更新。本警示性聲明對所有前瞻性陳述進行了全面限定。
Attachment
附件
- 20240716_ACIU_AAIC-curtain raiser-CLEAN
- 20240716_aciu_AAIC-窗簾升降機-清潔
Source: AC Immune SA
來源:AC Immune SA